Company Profile
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Latest News

What Could Go Wrong With Recursion Pharmaceuticals Stock?

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Schrödinger (SDGR) Could Be 29% Below Fair Value Despite A 38% Overvalued View

Schrodinger Stock Has Technical Strength as It Hits New 2-Year Highs
Schrodinger Insider Sold Shares Worth $927,970, According to a Recent SEC Filing
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data